ADVERTISEMENT

Cipla - Regulatory Risks On The Rise: Motilal Oswal

The U.S. FDA inspected Cipla’s Pithampur site between Feb 6 and Feb 17, 2023 and issued form 483 with eight observations.

<div class="paragraphs"><p>Cipla Ltd. (Source: Company website)</p></div>
Cipla Ltd. (Source: Company website)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.  
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit